To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program ...